222 related articles for article (PubMed ID: 17659485)
1. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
2. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
3. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
4. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
[TBL] [Abstract][Full Text] [Related]
5. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
6. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
[TBL] [Abstract][Full Text] [Related]
7. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
8. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
9. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
[TBL] [Abstract][Full Text] [Related]
10. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
12. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.
Wulff H
Expert Opin Ther Pat; 2010 Dec; 20(12):1759-65. PubMed ID: 20954790
[TBL] [Abstract][Full Text] [Related]
13. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
14. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
15. Potassium channels, memory T cells, and multiple sclerosis.
Beeton C; Chandy KG
Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
[TBL] [Abstract][Full Text] [Related]
16. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
Harvey AJ; Baell JB; Toovey N; Homerick D; Wulff H
J Med Chem; 2006 Feb; 49(4):1433-41. PubMed ID: 16480279
[TBL] [Abstract][Full Text] [Related]
17. Novel Kv1.3 blockers for immunosuppression: WO2012155199.
Nguyen W
Expert Opin Ther Pat; 2013 Nov; 23(11):1511-6. PubMed ID: 23968576
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.
Villalonga N; David M; Bielańska J; González T; Parra D; Soler C; Comes N; Valenzuela C; Felipe A
Biochem Pharmacol; 2010 Sep; 80(6):858-66. PubMed ID: 20488163
[TBL] [Abstract][Full Text] [Related]
19. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.
Azam P; Sankaranarayanan A; Homerick D; Griffey S; Wulff H
J Invest Dermatol; 2007 Jun; 127(6):1419-29. PubMed ID: 17273162
[TBL] [Abstract][Full Text] [Related]
20. A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.
Harvey AJ; Gable RW; Baell JB
Bioorg Med Chem Lett; 2005 Jul; 15(13):3193-6. PubMed ID: 15935664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]